ArticleFrontiers in oncology2025
MDA-MB-231 breast cancer cells adapted to anchorage-independent growth reveal senescent-like phenotype and persistent downregulation of PD-L1 expression.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metastasis remains the primary cause of mortality in breast cancer, particularly in aggressive triple-negative (TNBC) subtypes. A crucial yet understudied aspect of this process involves cancer cell survival in a detached state and subsequent reattachment at distant sites. While Methods: We generated clones of MDA-MB-231 TNBC cells through consecutive selection for enhanced anchorage-independent survival. This was achieved using 2-deoxy-D-glucose (2DG) alone, 2DG combined with metformin, or Poly(2-hydroxyethyl methacrylate) (polyHEMA)-coated surfaces. The resulting adapted clones were characterized by RNA transcriptomics, comparing them to one-time treated non-selected cells. Real-time cellular energy metabolism was assessed via Seahorse analysis, while mitochondrial mass and intracellular localization were determined by flow cytometry and fluorescent microscopy, respectively. Results: Transcriptomic analysis of the MDA-MB-231 clones adapted to anchorage-independent growth revealed distinct alterations in gene expression, confirmed by principal component analysis showing clear separation from control clusters. These adapted clones exhibited increased mesenchymal and stemness markers, downregulated cell cycle genes, and a senescent-like phenotype. Interestingly, while nuclear-encoded oxidative phosphorylation (OxPhos) genes were downregulated, mitochondrial-encoded OxPhos genes were upregulated, with no significant shift in overall ATP production as measured by Seahorse analysis. Paradoxically, despite increased Discussion: Our adapted clones provide a novel
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.